Chebulinic acid is a safe and effective antiangiogenic agent in collagen-induced arthritis in mice

• Published in: Arthritis research & therapy Vol. 22; no. 1; p. 273
• Main Authors: Lu, Kai, Iwenofu, O. Hans, Mitra, Rita, Mo, Xiaokui, Dasgupta, Partha Sarathi, Basu, Sujit
• Format: Journal Article
• Language: English
• Published: England BioMed Central 23.11.2020
• Subjects: Angiogenesis; Angiogenesis Inhibitors - pharmacology; Animals; Antibodies; Arthritis; Arthritis, Experimental - drug therapy; Blood pressure; Cartilage; Collagen; Edema; Experiments; Government agencies; Human subjects; Humans; Hydrolyzable Tannins; Hypertension; Kinases; Males; Mice; Mice, Inbred DBA; Rheumatoid arthritis; Synovial Membrane; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A; United States > US; Angiogenesis; Chebulinic acid; Treatment; Collagen-induced arthritis; Rheumatoid arthritis; VEGF
• ISSN: 1478-6362; 1478-6354; 1478-6362
• DOI: 10.1186/s13075-020-02370-1

Although vascular endothelial growth factor-A (VEGF)-induced angiogenesis has been reported to play an important role in the pathogenesis of rheumatoid arthritis (RA), serious side effects, mainly grade 2-3 hypertension, which is commonly observed with currently available anti-VEGF agents, can be detrimental for RA patients due to hypertension and associated cardiovascular complications seen in these patients. Thus, identification of anti-VEGF molecules that do not increase blood pressure could be useful for the treatment of RA. Chebulinic acid (CI), a water-soluble small-molecule tannin, can inhibit the actions of VEGF, and a report suggested that CI might not increase blood pressure due to its compensatory effects on the cardiovascular system. Therefore, the effects of CI on blood pressure in mice and the progression of the disease in a murine collagen-induced arthritis (CIA) model were investigated. CIA was induced in DBA/1J mice with type II collagen. The effects of CI in these animals were then evaluated by determination of clinical, histopathological, and immunohistochemical parameters. The effects of CI on VEGF-induced proangiogenic genes and signaling pathways were examined in vitro and in vivo. Significant CD31 and VEGF expressions were detected in the synovial tissues of mice with CIA, similar to their expressions observed in human RA patients. However, treatment with CI significantly inhibited paw swelling, decreased the mean articular index and joint pathology scores in these animals through inhibition of VEGF-induced proangiogenic gene expressions and signaling pathways that regulate angiogenesis. Unlike currently used antiangiogenic agents, CI at a dose that inhibits VEGF actions did not increase blood pressure in mice. CI can act as a safe and potent anti-VEGF antiangiogenic agent for the treatment of types of inflammatory arthritis, such as RA.